Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
The DOI matches its Crossref record; 415 of the 415 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. PARTICIPANTS: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. EVIDENCE: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. CONSENSUS PROCESS: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. CONCLUSIONS: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screen women before initiating MHT for cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use of MHT to prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not use MHT. Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have not associated HRT in women 40-49 years with increased risk of breast cancer (161), and there is no evidence that estrogen replacement in women with premature ovarian failure relates to a higher risk of breast cancer ( 162).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [162]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889 · cited 3×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
Background2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in development and implementation of evidence-based guidelines (1).”
Method2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534 · cited 2×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
BackgroundClinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149 · cited 2×
“Recent guidelines address bonespecific therapies (43).”
BackgroundWriting Group Members, Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S. M., Ho, M., Howard, V., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.187998 · Cited by 3,711
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Cited by
Items 201–300 of 883
Optimizing sexual and reproductive health across the lifespan in people with cystic fibrosis
West, N. E., Kazmerski, T. M., Taylor‐Cousar, J. L., Tangpricha, V., Pearson, K., Aitken, M. L., & Jain, R. (2021) · Pediatric Pulmonology · doi:10.1002/ppul.25703 · Cited by 26
“women without CF is commonly extrapolated, such as the benefits and risks of hormone replacement therapy (HRT) to alleviate menopausal symptoms.(110) In women without CF, the benefits of HRT for those aged 50–59 years may include a trend toward less bone fractures, improved diabetes control, and all‐cause mortality, b…”
Exogenous reproductive hormone use in breast cancer survivors and previvors
Vaz-Luís, I., & Partridge, A. H. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.207 · Cited by 28
Hormone therapy and breast cancer: emerging steroid receptor mechanisms
Perkins, M., Toit, R. L.-D., & Africander, D. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0094 · Cited by 29
Managing vasomotor symptoms in women after cancer
Pinkerton, J. V., & Santen, R. J. (2019) · Climacteric · doi:10.1080/13697137.2019.1600501 · Cited by 27
Self-citationHuang, Y., Qi, T., Ma, L., Li, D., Li, C., Lan, Y., Chu, K., Chen, P., Xu, W., Cao, Y., et al. (2021) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001733 · Cited by 24
“Vasomotor symptoms (VMS), such as hot flashes and night sweats, are considered hallmarks of the transition to the menopause and often the most troublesome symptoms of menopause, affecting up to 80% of women in Western countries and about 35% to 60% of women in China.(10,12,15,16)”
BackgroundInfluentialOophorectomy and rate of dementia: a prospective cohort study
Uldbjerg, C. S., Wilson, L. F., Koch, T., Christensen, J., Dehlendorff, C., Priskorn, L., Abildgaard, J., Simonsen, M. K., Lim, Y.-H., Jørgensen, J. T., et al. (2022) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001943 · Cited by 25
“Following premenopausal oophorectomy, hormone therapy (HT) is often recommended until the average age of menopause (around 51 y) to prevent the adverse consequences of premature estrogen loss.(11,12) The evidence linking HT use to dementia is conflicting and based on postmenopausal women, with one large observational…”
BackgroundApplications of the Internet of Medical Things to Type 1 Diabetes Mellitus
Rodríguez‐Rodríguez, I., Rodríguez, J., & Campo-Valera, M. (2023) · Electronics · doi:10.3390/electronics12030756 · Cited by 31
A pragmatic approach to the management of menopause
Lega, I. C., Fine, A., Lam-Antoniades, M., & Jacobson, M. R. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.221438 · Cited by 36
“40 In the WHI 20-year follow-up study, patients on conjugated estrogen alone showed a lower risk of breast cancer than those on placebo.”
BackgroundCanonico, M., & Scarabin, P. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000665 · Cited by 24
“Importantly, the Endocrine Society made a strong recommendation for using nonoral route of HT among women at increased VTE risk.(21) This is good news for the health of postmenopausal women who consider HT and a nudge in the right direction.”
Liang, Y., Jiao, H., Qu, L., & Liu, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.802959 · Cited by 26
Sobel, T. H., & Shen, W. (2022) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001938 · Cited by 27
“’’.(28) However, there is limited evidence on how transdermal MHT use affects VTE events in these high-risk women.”
BackgroundSivasinprasasn, S., Tanajak, P., Pongkan, W., Pratchayasakul, W., Chattipakorn, S. C., & Chattipakorn, N. (2017) · Scientific Reports · doi:10.1038/srep44306 · Cited by 24
“Hormone therapy is an effective remedy for the management of menopausal-related problems such as bone health, reproductive tract symptoms, and vasomotor symptoms 7 .”
InfluentialMonteiro, N. E. S., de Queirós, L. D., Lopes, D. B., Pedro, A. O., & Macêdo, G. A. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.12.043 · Cited by 25
Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions
Mukherjee, A., & Davis, S. R. (2025) · Clinical Endocrinology · doi:10.1111/cen.15211 · Cited by 39
Self-citationTextbook of Women’s Reproductive Mental Health
(2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379545 · Cited by 33
Not All Maca Is Created Equal: A Review of Colors, Nutrition, Phytochemicals, and Clinical Uses
Minich, D. M., Ross, K., Frame, J., Fahoum, M., Warner, W., & Meissner, H. O. (2024) · Nutrients · doi:10.3390/nu16040530 · Cited by 35
Marsden, J., Marsh, M., Rigg, A. S., & on behalf of The British Menopause Society (2019) · Post Reproductive Health · doi:10.1177/2053369118824920 · Cited by 23
Koebele, S. V., Nishimura, K., Bimonte‐Nelson, H. A., Kemmou, S., Ortiz, J. B., Judd, J. M., & Conrad, C. D. (2019) · Hormones and Behavior · doi:10.1016/j.yhbeh.2019.104656 · Cited by 26
“There is an overall consensus regarding the safety and effectiveness of hormone therapy use supported by professional organizations that provide clinical recommendations for menopause care and treatment, such as the North American Menopause Society (NAMS), the Endocrine Society, the American College of Obstetricians a…”
BackgroundMechanistic Effects of Estrogens on Breast Cancer
Santen, R. J., Stuenkel, C. A., & Yue, W. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000596 · Cited by 23
“When considering the use of MHT in postmenopausal women, one needs to calculate a personalized risk, based on individual characteristics.163 Not emphasized previously in the literature is that underlying risk is an important factor in determining individual risk imparted by MHT.”
ResultInfluentialSelf-citationZhang, J., Bai, W., Wang, W., Jiang, H., Jin, B., Liu, Y., Liu, S., Wang, K., Jia, J., & Qin, L. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.04.029 · Cited by 24
“5 potentially serious side effects, such as cardiovascular events and breast carcinoma (Nelson et al., 2006; Stuenkel et al., 2015).”
BackgroundAcute and Preventive Management of Migraine during Menstruation and Menopause
Ornello, R., Matteis, E. D., Felice, C. D., Caponnetto, V., Pistoia, F., & Sacco, S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112263 · Cited by 26
“HRT is usually prescribed to reduce the vasomotor symptoms associated with the menopausal transition [100,101].”
BackgroundYue, W., Wang, J., Atkins, K. A., Bottalico, L. N., Mesaros, C., Blair, I. A., & Santen, R. J. (2018) · International Journal of Cancer · doi:10.1002/ijc.31401 · Cited by 21
“Menopausal hormone therapy (MHT) is the most effective treatment for symptoms while for increased bone resorption, MHT as well as bisphosphosphonates and denosumab are effective.(1) The most prescribed therapy for menopause in the United States histor-”
BackgroundSelf-citationManaging menopausal vasomotor symptoms in older women
Stuenkel, C. A. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.08.005 · Cited by 25
Self-citationVasomotor symptoms, sleep problems, and depressive symptoms in community‐dwelling Japanese women
Tomida, M., Otsuka, R., Tange, C., Nishita, Y., Kimura, T., Stoelzel, M., Tanaka‐Amino, K., Shimokata, H., & Terauchi, M. (2021) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14937 · Cited by 21
DePree, B., Houghton, K., DiBenedetti, D. B., Shiozawa, A., King, D. D., Kim, J., & Mancuso, S. (2022) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002096 · Cited by 22
Reproductive milestones across the lifespan and cardiovascular disease risk in women
Stuenkel, C. A. (2023) · Climacteric · doi:10.1080/13697137.2023.2259793 · Cited by 25
“…recommendations include – in the absence of contraindications or elevated CVD or breast cancer risks – starting hormone therapy promptly following diagnosis and continuing until the anticipated age of natural menopause when the advisability of continuing can be reassessed [57,83,85,94–99].”
BackgroundInfluentialSelf-citationJohnson, J., Lawley, S. D., Emerson, J. W., & Oktay, K. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2023.12.037 · Cited by 23
Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy
Shin, J. J., Kim, S. K., Lee, J. R., & Suh, C. S. (2017) · Journal of Menopausal Medicine · doi:10.6118/jmm.2017.23.2.79 · Cited by 20
“However, the Endocrine Society recommended against the use of ospemifene in their recent clinical practice guideline.(30)”
MethodGuideline No. 422e: Menopause and Cardiovascular Disease
Abramson, B. L., Black, D., Christakis, M. K., Fortier, M. P., & Wolfman, W. (2021) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2021.09.010 · Cited by 20
Chen, K. L. A., Zhao, Y. C., Hieronymi, K., Smith, B. P., & Madak-Erdogan, Z. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189911 · Cited by 19
Thrombotic risk associated with gender-affirming hormone therapy
Mullins, T. L. K., & Mullins, E. S. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.05.015 · Cited by 23
M, M. S. C., Wu, X., Wang, X., Miyazaki, K., Morga, A., Nappi, R. E., Stute, P., Martins, K., & Schaudig, K. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108159 · Cited by 26
“Hormone therapy (HT) is currently the principal treatment for VMS associated with menopause, but it is not appropriate for everyone [9,10].”
InfluentialReproductive aging in biological females: mechanisms and immediate consequences
Muhammad, Y. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1658592 · Cited by 30
“Nonetheless, Menopausal hormone therapy (MHT) continues to be a recommended option for managing moderate to severe vasomotor symptoms, such as hot fl ashes, when prescribed at the lowest effective dose and for the shortest period needed (254, 255).”
Menopausal Hormone Therapy—Risks, Benefits and Emerging Options: A Narrative Review
Arnautu, A. M., Nimigean, V. R., Nacea, C. A., Tilici, D.-M., & Păun, D. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211098 · Cited by 30
Menopausal hormone therapy for women living with HIV
King, E. M., Prior, J. C., Pick, N., van Schalkwyk, J., Kestler, M., Tkachuk, S., Loutfy, M. R., & Murray, M. C. M. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00148-x · Cited by 20
The Menopause Management Vacuum
Faubion, S. S., & SHUFELT, C. L. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000594 · Cited by 22
Ren, Q., Yu, X., Liao, F., Chen, X., Yan, D., Nie, H., Fang, J., Yang, M., & Zhou, X. (2018) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2018.03.012 · Cited by 23
Kim, J.-E., Choi, J., Park, J., Lee, J., Shin, A., Park, S. M., Kang, D., & Choi, J. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.12.012 · Cited by 25
Kargozar, R., Salari, R., Jarahi, L., Yousefi, M., Pourhoseini, S. A., Sahebkar-Khorasani, M., & Azizi, H. (2019) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.04.003 · Cited by 23
Koebele, S. V., Mennenga, S. E., Poisson, M. L., Hewitt, L. T., Patel, S., Mayer, L. P., Dyer, C. A., & Bimonte‐Nelson, H. A. (2020) · Hormones and Behavior · doi:10.1016/j.yhbeh.2020.104854 · Cited by 22
“Estrogen compound-containing hormone therapies are the only FDA-approved treatment that alleviates the broad spectrum of menopause-associated symptoms, from vaginal dryness to hot flashes (ACOG, 2014; Baber et al., 2016; Neves-E-Castro et al., 2015; Pinkerton et al., 2017; Stuenkel et al., 2015).”
BackgroundOspemifene for vulvar and vaginal atrophy: an overview
Palacios, S. (2020) · Drugs in Context · doi:10.7573/dic.2020-3-2 · Cited by 19
Vesco, K. K., Brooks, N. B., Francisco, M. C., Leo, M. C., Anderson, T. M., Kalter, M., & Clark, A. (2024) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002291 · Cited by 18
Mu, E., Chiu, L., & Kulkarni, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1528544 · Cited by 29
Viana, D. P. D. C., Câmara, L. C., & Palau, R. B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157074 · Cited by 24
“Moreover, it lacks robust anti-adipogenic, antifibrotic, or anti-inflammatory effects in adipose tissue [19,25,40].”
Rozenberg, S., Panay, N., Gambacciani, M., Cano, A., Gray, S., & Schaudig, K. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2219056 · Cited by 21
“To conclude the discussion it should be stressed that the recommendations from all the scientific societies underline that the benefits of personalized MHT outweigh the risks in symptomatic women [9,12,15,50].”
BackgroundUse of cardiovascular age for assessing risks and benefits of menopausal hormone therapy
Santen, R. J. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000847 · Cited by 20
Self-citationMenopause and its Cardiometabolic Consequences: Current Perspectives
Anagnostis, P. G., & Goulis, D. G. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117999190228123237 · Cited by 22
Li, Y., Xia, G., Tan, Y., & Shuai, J. (2020) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2020.101244 · Cited by 20
The Negative Impacts of Acromegaly on Bone Microstructure Not Fully Reversible
Duan, L., Yang, S., Wang, L. J., Zhang, Y., Li, R., Yang, H., Zhao, Y., Du, H., Zhai, X., Gong, F., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.738895 · Cited by 19
Approach to the Patient With New-Onset Secondary Amenorrhea: Is This Primary Ovarian Insufficiency?
Stuenkel, C. A., Gompel, A., Davis, S. R., Pinkerton, J. V., Lumsden, M. A., & Santen, R. J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab766 · Cited by 23
Self-citationManagement of vasomotor symptoms in cancer patients
Zhu, L., Hshieh, T. T., Iyer, T. K., Morgans, A. K., & Hamnvik, O. R. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf002 · Cited by 23
“4 The concern with using HT arose following the early findings of the Women’s Health Initiative (WHI), which evaluated the benefits and risks of conjugated equine estrogens combined with medroxyprogesterone acetate (MPA), compared with placebo in healthy postmenopausal women.”
InfluentialVasomotor Symptoms: More Than Temporary Menopausal Symptoms
Ryu, K.-J., Park, H., Park, J. S., Lee, Y. W., Kim, S. Y., Kim, H.-Y., Jeong, Y., Kim, Y. J., Yi, K. W., Shin, J., et al. (2020) · Journal of Menopausal Medicine · doi:10.6118/jmm.20030 · Cited by 23
“International guidelines recommend hormone replacement therapy (HRT) for management of VMS in selected cases [4,5].”
BackgroundHoang, V. T., Nguyen, H.-P., Nguyen, V. N., Hoang, D. M., Nguyen, T.-S. T., & Thanh, L. N. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.956274 · Cited by 21
“Estrogen replacement therapy is commonly prescribed to treat postmenopausal syndromes (Kovalevsky 2005; Simpson and Santen 2015; Stuenkel et al., 2015).”
BackgroundYuk, J. (2024) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.15461 · Cited by 17
Meda, C., Benedusi, V., Cherubini, A., Valenti, L. V. C., Maggi, A. C., & Torre, S. D. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101143 · Cited by 24
“28 We also differentiated women according to MASLD status.”
The impact of female sex hormones on cardiovascular disease: from mechanisms to hormone therapy
Kan, Y., Peng, Y., Zhao, Z.-H., Dong, S., Xu, Y.-X., Ma, X., Liu, X., Liu, Y., & Yu-Jie, Z. H. O. U. (2024) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2024.06.003 · Cited by 28
Du, J., Liu, J., Wang, X., Wang, X., Ma, Y., Zhang, S., Li, Z., Ma, J., & Liu, J. (2025) · Biology Direct · doi:10.1186/s13062-025-00618-x · Cited by 23
“However, given the complex balance between risks and benefits and because the impact of MHT on diabetes prevention is not a primary outcome in RCTs, MHT is neither appropriate nor FDA-approved for preventing T2D in women [144].”
Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer
Frampton, J. E. (2017) · Drugs · doi:10.1007/s40265-017-0849-3 · Cited by 17
“3 summarizes the QOL impact of OFS plus OAET combination therapy on a number of key endocrine symptom/adverse event indicators, including hot flushes and night sweats (the hallmarks of menopause [43]).”
BackgroundFinancial Conflicts of Interest Among Authors of Endocrine Society Clinical Practice Guidelines*
Irwig, M. S., Kyinn, M., & Shefa, M. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00526 · Cited by 20
“Menopause (24) Endocrine Society 2015 7 3 No 3 2 3 1 111 433 Polycystic ovary syndrome (25) Endocrine Society 2013 7 1 No 1 M 5 2 237 115 Lipids Hypertriglyceridemia (26) Endocrine Society 2012 7 6 Yes 6 M 4 1 172 1207 Male reproductive Testosterone therapy (27) Endocrine Society 2010 7 6 Yes 5 5 5 6 118 6756 Obesity…”
Çılgın, H. (2019) · The Scientific World JOURNAL · doi:10.1155/2019/1814804 · Cited by 18
Vesco, K. K., Beadle, K., Stoneburner, A. B., Bulkley, J. E., Leo, M. C., & Clark, A. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001198 · Cited by 17
Menopausal symptom management in women with cardiovascular disease or vascular risk factors
Hirsch, H., & Manson, J. E. (2022) · Maturitas · doi:10.1016/j.maturitas.2022.01.016 · Cited by 19
Sex hormones and immune system: Menopausal hormone therapy in the context of COVID-19 pandemic
Averyanova, M., Vishnyakova, P., Yureneva, S. V., Yakushevskaya, O. V., Fatkhudinov, T., Elchaninov, A. V., & Sukhikh, G. T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.928171 · Cited by 25
The Beneficial and Adverse Effects of Phytoestrogens
Blázovics, A., Csorba, B., & Ferencz, A. (2022) · OBM Integrative and Complementary Medicine · doi:10.21926/obm.icm.2203034 · Cited by 17
Use of MHT in women with cardiovascular disease: a systematic review and meta-analysis
Bontempo, S., Yeganeh, L., Giri, R., & Vincent, A. J. (2023) · Climacteric · doi:10.1080/13697137.2023.2273524 · Cited by 25
“MHT is considered high risk in women with existing CVD or 10-year CVD risk ≥10% [9,13] and in the setting of uncontrolled cardiac risk factors including blood pressure ≥180/110 mmHg, total cholesterol >7.8 mmol/L and triglycerides > 4.5 mmol/L [8,9].”
BackgroundInfluentialNyrønning, L. Å., Videm, V., Romundstad, P., Hultgren, R., & Mattsson, E. J. R. (2019) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2019.02.032 · Cited by 19
Spontaneous coronary artery dissection: etiology and recurrence
Tan, N. Y. L., & Tweet, M. S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1635011 · Cited by 18
“Similarly, for postmenopausal women who experience SCAD while on hormone therapy, some consideration should be given towards adjusting the therapy such as using the lowest effective dose or trialing non-hormonal alternatives [127,128].”
BackgroundEstradiol treatment improves biological rhythms in a preclinical rat model of menopause
Yin, W., Borniger, J. C., Wang, X., Maguire, S. M., Munselle, M. L., Bezner, K. S., Tesfamariam, H. M., Garcia, A. N., Hofmann, H. A., Nelson, R. J., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.029 · Cited by 18
“It is likely that many of the dysfunctions of menopause occur because of the confluence of these processes, including sleep disturbances, anxiety, changes in metabolism, and cognitive and affective impairments (Mauvais-Jarvis et al., 2013; Stuenkel et al., 2015).”
BackgroundMANAGEMENT OF ENDOCRINE DISEASE: Flushing: current concepts
Huguet, I., & Grossman, A. B. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0295 · Cited by 19
O’Brien, K. M., House, M., Goldberg, M., Jones, M. E., Weinberg, C. R., de González, A. B., Bertrand, K. A., Blot, W. J., DeHart, J. C., Couch, F. J., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00211-6 · Cited by 18
Intraovarian PRP Injection Improved Hot Flashes in a Woman With Very Low Ovarian Reserve
Merhi, Z. O., Seckin, S. I., & Mouanness, M. (2021) · Reproductive Sciences · doi:10.1007/s43032-021-00655-7 · Cited by 16
“Administration of PRP can be useful for younger women who undergo POI, particularly when HRT is contraindicated, such as in patients who have increased risk for thrombophilia, including those with SLE, migraine with aura, as well as active liver disease, or history of hormone-positive malignancy [21].”
BackgroundCasale, M., Baldini, M., Monte, P. D., Gigante, A., Grandone, A., Origa, R., Poggi, M., Gadda, F., Lai, R., Marchetti, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071826 · Cited by 21
Hormones and thrombosis: risk across the reproductive years and beyond
Machin, N., & Ragni, M. V. (2020) · Translational research · doi:10.1016/j.trsl.2020.06.011 · Cited by 23
Menopausal Hormone Therapy and the Role of Estrogen
Stuenkel, C. A. (2021) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000648 · Cited by 19
Self-citationKoebele, S. V., Hiroi, R., Plumley, Z. M. T., Melikian, R., Prakapenka, A. V., Patel, S., Carson, C. G., Kirby, D., Mennenga, S. E., Mayer, L. P., et al. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.696838 · Cited by 22
Jang, D., Lee, E., Lee, S., Kwon, Y.-S., Kang, K. S., Kim, C.-E., & Kim, D. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03608-y · Cited by 17
“Hormone replacement therapy (HRT), also known as menopausal hormone therapy or postmenopausal hormone therapy, is used to treat various symptoms involved in menopause [9], and it has been reported that HRT can alleviate obesity and its related symptoms [10–12].”
BackgroundStuenkel, C. A. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.05.006 · Cited by 19
Self-citationCystic fibrosis-related bone disease: an update on screening, diagnosis, and treatment
Cobb, C., Wu, M., & Tangpricha, V. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251328210 · Cited by 15
“119 There are no large studies examining the use of HT in peri/ postmenopausal women with CF, including estrogen, progesterone, or testosterone.”
From Menstruation to Menopause: Have We Medicalised the Physiology of Normalcy? (Part 1)
Laura, R. S. (2017) · Women s Health - Open Journal · doi:10.17140/whoj-3-e016 · Cited by 14
Using menopausal hormone therapy after a cancer diagnosis in Ireland
Donohoe, F., O’Meara, Y., Roberts, A., Comerford, L., Kelly, C. M., Walshe, J. M., Lundy, D., Hickey, M., & Brennan, D. J. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-02947-6 · Cited by 16
Oral hormonal contraceptives and cardiovascular risks in females
Bhullar, S. K., Rabinovich-Nikitin, I., & Kirshenbaum, L. A. (2024) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2024-0041 · Cited by 17
Felicetti, F. C., Castiglione, A., Biasin, E., Fortunati, N., Dionisi‐Vici, M., Matarazzo, P., Ciccone, G., Fagioli, F., & Brignardello, E. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28709 · Cited by 15
Rapid Jetlag Resetting of Behavioral, Physiological, and Molecular Rhythms in Proestrous Female Mice
Pilorz, V., Kolms, B., & Oster, H. (2020) · Journal of Biological Rhythms · doi:10.1177/0748730420965291 · Cited by 16
“There is a strong evidence from animal models that estradiol replacement in aging females mitigates many symptoms such as changes in metabolism and locomotor activity (Mauvais-Jarvis et al., 2013; Stuenkel et al., 2015; Yin et al., 2019).”
BackgroundMenopause and gastrointestinal health and disease
Ley, D., & Saha, S. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01075-7 · Cited by 19
“HRT is considered safe and effective for those who are low risk, including women without a history of cardiac disease or breast cancer, those 60 years of age and those who are 10 years from the onset of menopause 22 .”
Female-specific risk factors for cardiovascular disease: an update
Theodorou, A., Karagiannakis, D. S., Stefanaki, K., Kassi, E., Peppa, Μ., Vryonidou, A., & Paschou, S. Α. (2024) · HORMONES · doi:10.1007/s42000-024-00576-5 · Cited by 16
“Furthermore, HRT has been shown to reduce the risk of T2DM by 14–19% [34].”
Patient experience of menopause care after breast cancer in the UK: a cross-sectional study
Glynne, S., Reisel, D., Kamal, A., & Newson, L. R. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002504 · Cited by 14
Estrategias de manejo durante el climaterio y menopausia. Guía práctica de atención rápida
Ayala-Peralta, F. (2020) · Revista Peruana de Investigación Materno Perinatal · doi:10.33421/inmp.2020204 · Cited by 33
Compounded bioidentical menopausal hormone therapy – a physician perspective
Stuenkel, C. A. (2020) · Climacteric · doi:10.1080/13697137.2020.1825668 · Cited by 15
Self-citationRecent Advancements in Engineered Biomaterials for the Regeneration of Female Reproductive Organs
Kim, S. W., Kim, Y. Y., Kim, H., & Ku, S. (2021) · Reproductive Sciences · doi:10.1007/s43032-021-00553-y · Cited by 15
“HRT is a management option for ovarian failure after cancer treatment and results in osteoporosis and cardiovascular complications [93].”
BackgroundKim, H., & Lee, E. (2022) · Healthcare · doi:10.3390/healthcare10112121 · Cited by 13
“Stabilized IPTW weights were generated using prognostically or clinically important information such as socioeconomic, reproductive, and clinical characteristics [7,8,27].”
MethodResultWildemeersch, D. A. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1177014 · Cited by 13
Fokialakis, N., Alexi, X., Aligiannis, N., Boulaka, A., Meligova, A. K., Lambrinidis, G., Kalpoutzakis, E., Pratsinis, H., Cheilari, A., Mitsiou, D. J., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210247 · Cited by 15
Cardiovascular Risk/Benefit Profile of MHT
Villa, P., Amar, I. D., Shachor, M., Cipolla, C., Ingravalle, F., & Scambia, G. (2019) · Medicina · doi:10.3390/medicina55090571 · Cited by 17
“For women aged younger than 60 years or who are within 10 years past menopause onset, considering MHT for menopausal symptom relief, the endocrine society suggest evaluating the baseline risk of CVD and taking this risk into consideration when advising for or against MHT and when selecting type, dose, and route of adm…”
BackgroundMethodInfluentialSexual and reproductive health in cystic fibrosis
Frayman, K. B., Chin, M., Sawyer, S. M., & Bell, S. C. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000731 · Cited by 14
“Comorbidities including long-standing CFRD, cystic fibrosis-related liver disease, and prior venous thrombosis should be taken into account if considering oestrogen-containing therapies for menopausal symptoms [61].”
BackgroundThe 2025 Menopausal Hormone Therapy Guidelines - Korean Society of Menopause
Kim, Y. J., Cho, M. K., Chung, Y., Hong, S.-H., Hwang, K. R., Jeon, G., Joo, J. K., Kim, S. K., Lee, D. O., Lee, D., et al. (2025) · Journal of Menopausal Medicine · doi:10.6118/jmm.25103 · Cited by 20
Management of menopause in women living with HIV – A comparative guideline review
Scofield, D., Moseholm, E., Aebi‐Popp, K., & Hachfeld, A. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.107937 · Cited by 17
“…Zealand College of Obstetricians and Gynaecologists (RANZOG) [33] Managing menopausal symptoms 2020 Australia New Zealand Endocrine Society (ENSO) [34] Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline 2015 International a Refers to the regional background…”
BackgroundMethodInfluentialSuriyaamporn, P., Kansom, T., Charoenying, T., Ngawhirunpat, T., Rojanarata, T., Patrojanasophon, P., Opanasopit, P., & Pamornpathomkul, B. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105646 · Cited by 12
Hypertension Management in Women With a Multidisciplinary Approach
Nobakht, N., Afshar, Y., Vaseghi, M., Li, Z., Donangelo, I., Lavretsky, H., Mok, T., Han, C. S., & Nicholas, S. B. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.10.005 · Cited by 19
Eriksson, R. G., Skalkidou, A., Cruz, N. C. R., Hirschberg, A. L., & Iliadis, S. I. (2025) · Maturitas · doi:10.1016/j.maturitas.2025.108263 · Cited by 12
Bondi, C., Ferrero, S., Scala, C., Tafi, E., Racca, A., Venturini, P. L., & Maggiore, U. L. R. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1218847 · Cited by 12
“) or excess cardiovascular or breast cancer risks [9,10].”
Background
Metadata
- Authors
- Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-11
- Volume
- 100
- Issue
- 11
- Pages
- 3975-4011
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2162957019
- Cited by
- 884
- References
- 414
- Citations by year
- 2026: 79 · 2025: 96 · 2024: 66 · 2023: 69 · 2022: 82 · 2021: 96 · 2020: 121 · 2019: 89 · 2018: 75 · 2017: 57 · 2016: 47 · 2015: 4
- FWCI
- 52.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- menopause, hormone replacement therapy, vasomotor symptoms, climacteric, postmenopausal women, cardiovascular risk screening, breast cancer risk, ospemifene, vaginal estrogen, genitourinary syndrome of menopause, vaginal moisturizers, lifestyle intervention, personalized treatment
- MeSH terms
- Contraindications, Age Factors, Breast Neoplasms, Cardiovascular Diseases, Female, Humans, Menopause, Terminology as Topic, Risk Factors, Severity of Illness Index, Estrogen Replacement Therapy, Evidence-Based Medicine, Hot Flashes, Female Urogenital Diseases, Venous Thromboembolism, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.